The Blocker Trap is the proprietary screening platform developed by Phylogica based on yeast genetics. The platform is designed to find "blockers" of protein interactions implicated in causing diseases.

The Blocker Trap has been engineered to enable genetic selection of highest affinity blockers (drug leads). It has a number of advantages as a screening tool:

• It can be used to screen millions of candidates concurrently

• It can be used to isolate peptides which bind with high affinity to a target and also disrupt a specific protein interaction

• It validates targets in a living test organism rather than in the test tube, which overcomes the early obstacles of general toxicity. If a lead compound is generally toxic to cells, it will kill the cells in the test, thereby saving futile expenditure on development

• The technology enables the selective elimination of insufficiently specific, non-target binding agents before preclinical testing, again potentially conferring considerable economic benefits to the pharmaceutical industry and overcoming a major drawback in drug development